Evidence map›Paper›PMID 41173907›Full record

ArticleScientific reports2025

Immunomodulation of behavior impairment via spleen-specific targeting lipid nanoparticles in a MeCP2 transgenic mouse model.

Shu Zhang, Yaxi Li, Bowen Yang, Aygun Teymur, Fatin Atrooz, Sheereen Majd, Chandra Mohan, Samina Salim, Tianfu Wu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Shu ZhangDepartment of Biomedical Engineering, University of Houston, Houston, TX, USA.
Yaxi LiDepartment of Biomedical Engineering, University of Houston, Houston, TX, USA.
Bowen YangDepartment of Biomedical Engineering, University of Houston, Houston, TX, USA.
Aygun TeymurDepartment of Biomedical Engineering, University of Houston, Houston, TX, USA.
Fatin AtroozDepartment of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, Houston, TX, USA.
Sheereen MajdDepartment of Biomedical Engineering, University of Houston, Houston, TX, USA.
Chandra MohanDepartment of Biomedical Engineering, University of Houston, Houston, TX, USA.
Samina SalimDepartment of Pharmacological and Pharmaceutical Sciences, College of Pharmacy, University of Houston, Houston, TX, USA.
Tianfu WuDepartment of Biomedical Engineering, University of Houston, Houston, TX, USA. Twu13@central.uh.edu.

Funding

A biomarker panel based smart mini-array system for the homecare of autoimmune kidney diseasesR01AG062987 · NIA · UNIVERSITY OF HOUSTON · PI WU, TIANFU · 2019 to 2023
$2.2M
NIA NIH HHS R01 AG062987
6 · The paper itself

Abstract

This study investigates a novel approach using spleen-targeting lipid nanoparticles (LNPs) to immunomodulate behavioral impairment in a Methyl-CpG-binding protein 2 (Mecp2) transgenic mouse model. In a human Mecp2 transgenic mouse model (B6.Mecp2

Indexed as

Behavior, AnimalImmunomodulationLipidsMethyl-CpG-Binding Protein 2NanoparticlesSpleenAnimalsAutoantibodiesCytokinesDisease Models, AnimalHumansLiposomesMiceMice, TransgenicOligonucleotides, AntisenseAutoantibodiesCytokinesLipid NanoparticlesLipidsLiposomesMECP2 protein, humanMecp2 protein, mouseMethyl-CpG-Binding Protein 2Oligonucleotides, AntisenseDrug targetingImmunomodulationLipid nanoparticles (LNPs)MeCP2Neuropsychiatric disease

Identifiers

PMID41173907
PMCPMC12578921

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.